iRhythm Technologies (IRTC) investor relations material

VitalConnect acquisition strategy and product integration

• Acquisition aims to combine differentiated technology with strong commercial and clinical service capabilities, expanding the product portfolio to address the full MCT market, including 30-day monitoring and live look-in features.

• VitalConnect enables access to the remaining 30% of the MCT market not served by existing products, offering features like multi-vitals and downgrade ability, which are increasingly demanded by clinicians.

• Integration will leverage a larger sales force for nationwide launch, with plans to maintain both Zio MCT and VitalPatch as complementary offerings to address diverse customer needs.

• No immediate operational integration is planned; focus is on commercial rollout and training, with future opportunities for technology and algorithm integration.

• VitalConnect's $65 million trailing revenue is expected to grow with expanded commercial reach, and gross margin improvements are anticipated through scale and operational efficiencies.

Market share, growth outlook, and financial targets

• Current MCT market share is in the mid-teens, with ambitions to reach 30%-40% over time, aiming for the number one position through innovation and portfolio expansion.

• MCT market is growing at 8%-9% annually, and the company holds over 70% share in long-term continuous monitoring, the largest segment.

• Guidance for 2027 targets over $1 billion in revenue and a 15% EBITDA margin, with limited cost synergies from the VitalConnect deal initially; future updates will follow acquisition closure.

• Q2 EBITDA margin was 19.3%, but increased investment in primary care and adjacent markets like sleep will reduce margins to 12%-13% in Q3, aligning with long-term growth strategy.

• Third-generation algorithm, launching in 2027, is expected to deliver $100 million in cumulative savings over five years, mainly through reduced technician review time.

Channel performance, EHR integration, and innovation

• Innovative channels now represent mid-single digits of revenue and are the fastest-growing segment, with high partner retention and expanding commercial programs.

• EHR integration is a key driver of LTCM growth, embedding products directly into customer workflows and accounting for over 50% of volume.

• Revenue per patient in innovative channels is consistent with company averages, with a high operating leverage model and direct billing to accounts.

• Multi-vitals capability is seen as a differentiator, supporting entry into new markets such as sleep apnea and heart failure monitoring, with ongoing R&D investment.

• Overlap exists between BioIntelliSense and VitalConnect technologies, with differentiation in SpO2 measurement and integration capabilities.